Vandetanib is a once-daily, oral anticancer agent that selectively inhibits vascular endothelial growth factor receptor (VEGFR), RET and EGFR signaling [18,19], and is licensed for the treatment of MTC in several geographical regions. This evidence concerns the gene RET and medullary thyroid gland carcinoma.